Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

08:12
10/10/16
10/10
08:12
10/10/16
08:12

Merck should strengthen leadership in first line NSCLC, says BMO Capital

BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.

TODAY'S FREE FLY STORIES

NXTM

NxStage Medical

$23.46

0.13 (0.56%)

21:43
06/26/17
06/26
21:43
06/26/17
21:43
Initiation
NxStage Medical initiated  »

NxStage Medical initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

21:40
06/26/17
06/26
21:40
06/26/17
21:40
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

BL

BlackLine

$37.80

-0.26 (-0.68%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
BlackLine initiated  »

BlackLine initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTI

Ultimate Software

$221.91

-0.25 (-0.11%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Ultimate Software initiated  »

Ultimate Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

CRM

Salesforce

$88.11

-0.51 (-0.58%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Salesforce initiated  »

Salesforce initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVBG

Everbridge

$24.66

-0.3 (-1.20%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Everbridge initiated  »

Everbridge initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNG

RingCentral

$37.65

-1 (-2.59%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
RingCentral initiated  »

RingCentral initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WK

Workiva

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Workiva initiated  »

Workiva initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBS

HubSpot

$68.20

-0.7 (-1.02%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
HubSpot initiated  »

HubSpot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

HUBS

HubSpot

$68.20

-0.7 (-1.02%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
HubSpot initiated  »

HubSpot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

QTWO

Q2 Holdings

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Q2 Holdings initiated  »

Q2 Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

INST

Instructure

$29.55

0.4 (1.37%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Instructure initiated  »

Instructure initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

MANH

Manhattan Associates

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Manhattan Associates initiated  »

Manhattan Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCTY

Paylocity

$47.39

-1.65 (-3.36%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Paylocity initiated  »

Paylocity initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

SHOP

Shopify

$92.04

-2.44 (-2.58%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Shopify initiated  »

Shopify initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LH

LabCorp

$152.30

0.68 (0.45%)

20:10
06/26/17
06/26
20:10
06/26/17
20:10
Downgrade
LabCorp rating change  »

LabCorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATXI

Avenue Therapeutics

20:06
06/26/17
06/26
20:06
06/26/17
20:06
Syndicate
Avenue Therapeutics 5.5M share IPO priced at $6.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

NXPI

NXP Semiconductors

$109.73

-0.25 (-0.23%)

20:05
06/26/17
06/26
20:05
06/26/17
20:05
Hot Stocks
NXP Semi collaborates with Shanghai Unicom, roam2free on eSIM solution »

NXP Semiconductors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

PDCE

PDC Energy

$42.88

-1.84 (-4.11%)

19:21
06/26/17
06/26
19:21
06/26/17
19:21
Hot Stocks
PDC Energy CEO 'disappointed' with Clean Air Act complaint »

Today, the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MRIN

Marin Software

$1.18

0.025 (2.17%)

19:17
06/26/17
06/26
19:17
06/26/17
19:17
Hot Stocks
Marin Software names Brad Kinnish CFO »

Marin Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$34.52

0.32 (0.94%)

19:15
06/26/17
06/26
19:15
06/26/17
19:15
Earnings
General Motors: Previous FY17 EPS view unchanged »

General Motors said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

GM

General Motors

$34.52

0.32 (0.94%)

19:04
06/26/17
06/26
19:04
06/26/17
19:04
Hot Stocks
General Motors lowers view of 2017 U.S. car industry »

On a conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

BLKB

Blackbaud

$89.25

-0.25 (-0.28%)

, CST

CST Brands

$48.54

0.18 (0.37%)

18:56
06/26/17
06/26
18:56
06/26/17
18:56
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P SmallCap 600…

BLKB

Blackbaud

$89.25

-0.25 (-0.28%)

CST

CST Brands

$48.54

0.18 (0.37%)

NSA

National Storage

$22.63

0.22 (0.98%)

ANCUF

Alimentation Couche-Tard

$48.08

1.9887 (4.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$34.52

0.32 (0.94%)

18:52
06/26/17
06/26
18:52
06/26/17
18:52
Hot Stocks
General Motors raises expected Opel sale charge to $5.5B »

On a conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

WMT

Wal-Mart

$75.50

0.66 (0.88%)

18:43
06/26/17
06/26
18:43
06/26/17
18:43
Periodicals
Wal-Mart sued for wrongful death of Illinois Uber driver, Reuters reports »

The family of an Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.